Norway makes fishing vessel data accessible to the world

Norway to become first European nation to share its vessel tracking information on Global Fishing Watch map

Lisbon, Portugal, June 30, 2022 (GLOBE NEWSWIRE) — Norway has become the first country in Europe to partner with Global Fishing Watch—an international nonprofit organization dedicated to advancing ocean governance through increased transparency—and will share its vessel tracking data for the Norwegian fishing fleet on the organization’s public map.

The announcement was made at the second United Nations Ocean Conference in Lisbon, Portugal where countries from around the world are gathering to mobilize action and innovative solutions to some of the ocean’s most pressing threats.

Under the memorandum of understanding, which was signed between Global Fishing Watch and Norway’s Directorate of Fisheries, Norway has agreed to share the vessel monitoring system data for vessels 15 meters or more in length on the Global Fishing Watch map.

“Wild living marine resources are a common good and belong to everyone,” said Frank Bakke-Jensen, director general of the Directorate of Fisheries in Norway. “When a commercial fishing fleet is licensed to utilize this common good, we are obliged and committed to share fisheries data documenting the environmental footprint of commercial fishing activity. We hope that others will follow this approach and share more fisheries data.”

“We believe that improved transparency of fishing data is necessary to reduce the risk of illegal fisheries and set the groundwork for improved compliance,” said Thord Monsen, head of monitoring, control and surveillance at the Directorate of Fisheries.

The incorporated data will span a total of approximately 600 vessels—all vessels 15 meters in length or more predominantly operating in Norwegian waters and the northeast Atlantic Ocean. Norway is currently expanding its VMS requirement to include all commercial fishing vessels, as well as increasing the frequency that vessels need to report their position—a requirement which will be implemented over the coming years in a phased approach.

“We’re seeing more and more countries embrace fisheries transparency, demonstrating their understanding of just how essential public data is to the effective management of fishing activity,” said Tony Long, chief executive officer of Global Fishing Watch. “Norway has taken a leading global role in the sustainable ocean economy and is using its experience and expertise to promote better ocean governance. By bringing its fishing fleet into our map, Norway is paving the way for other countries, including developed nations, to follow suit.”

Since October 2019 Norway has shared its VMS tracking information on the Fisheries Directorate website in support of transparency and as part of an effort to make government data public whenever possible. The partnership with Global Fishing Watch will help make its vessel tracking data more accessible to a wider range of stakeholders—a substantial benefit in the sphere of international fisheries management.

With a coastline of more than 83,000 kilometers, including islands and fjords, the fishing sector is a key element to Norway’s economic, social and cultural identity. Norway is the second largest exporter of fish and fish products by value in the world and is home to some of the most productive marine areas in the world. An influential voice when it comes to fisheries issues and a leader on blue economy issues, Norway’s decision to partner with Global Fishing Watch and amplify its vessel tracking data demonstrates how fisheries transparency can be adopted in countries where fishing represents such a significant part of the economy.

“Data can be a powerful tool in protecting the environment, as we have seen in our work on climate change. The more data we have about the ocean, the better we can protect it and the people that rely on it. Norway’s commitment to making fishing vessel data accessible to the world – via Global Fishing Watch – is a great step forward for ocean transparency,” said Michael R. Bloomberg, Founder of Bloomberg Philanthropies and ​UN Special Envoy on Climate Ambition and Solutions. “Their commitment to data-sharing is a model other countries can follow, and it will help demonstrate the effectiveness – environmentally and economically – of sustainable fishing.”

Norway joins a growing number of progressive countries from around the world that are dedicated to advancing, and benefiting from, fisheries transparency, which include: Benin, Brazil, Belize, Chile, Costa Rica, Ecuador, Panama, Peru and the Republic of the Marshall Islands.

Global Fishing Watch is an international nonprofit organization dedicated to advancing ocean governance through increased transparency of human activity at sea. By creating and publicly sharing map visualizations, data and analysis tools, we aim to enable scientific research and transform the way our ocean is managed. We believe human activity at sea should be public knowledge in order to safeguard the global ocean for the common good of all. globalfishingwatch.org

Attachment


Sarah Bladen
Global Fishing Watch
+44 79 20333832
sarah@globalfishingwatch.org

Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

June 30, 2022

Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix, Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, to incorporate the results of Biodesix’s Nodify Lung® blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data – along with the radiologic and patient history data currently used to determine treatment decisions – can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. Philips Lung Cancer Orchestrator solution is designed to enable health systems to operationalize lung cancer screening and lung nodule management programs at scale.

Lung cancer remains the leading cause of cancer deaths worldwide [1], with current 5-year survival rates after diagnosis typically less than 20% [2]. If detected and treated early, however, research shows 10-year survival rates could increase to more than 90% [3]. Thanks to the adoption of low-dose CT (computer tomography) screening and better management of incidental lung nodule findings, early-stage diagnosis and treatment is now possible, but has resulted in rapidly increasing caseloads. For example, recent changes in U.S. guidelines have nearly doubled the number of people now eligible for lung cancer screening [4].

“By incorporating Biodesix’s Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view,” said Louis Culot, General Manager Oncology Informatics and Genomics at Philips. “We expect the inclusion of Biodesix’s ground-breaking technology in Philips Lung Cancer Orchestrator to help drive more confident decisions for the care team, and ultimately benefit patients.”

As a next-step after radiologic lung nodule assessment, minimally-invasive biopsy procedures such as endobronchial biopsy (accessing a nodule via the patient’s airways), are already helping early-stage diagnosis. With 62% of biopsies conducted on benign nodules [5], by detecting the presence of blood-based biomarkers combined with clinical and radiomic factors, Biodesix’s Nodify Lung blood-based proteomic tests help clinicians to reclassify the risk of malignancy to better target resources to those who need them. If a nodule is malignant, the delay in surgical care for cancer patients by four weeks increases the mortality by 6-8% [6].

“We are delighted that our tests are being incorporated into Philips’ vision for end-to-end cancer care management using a multi-diagnostic approach,” said Scott Hutton, Chief Executive Officer at Biodesix. “By integrating our Nodify® tests in Philips Lung Cancer Orchestrator we hope to make these tests more accessible to physicians and patients and more easily utilized by care teams with the ultimate goal of improving patient care and outcomes.”

Philips Lung Cancer Orchestrator is an integrated patient management system for CT lung cancer screening programs and incidental lung nodule findings that keeps track of patients, appointments, diagnostic images, test results, and clinical decisions for every step of a lung cancer patient’s screening and treatment journey. Fitting seamlessly into conventional screening and diagnostic workflows, it coordinates the end-to-end patient journey to create a fully traceable, fully documented timeline of scheduled actions, and aggregates data on tumor staging, radiology, pathology, and biomarker analyses for informed decision-making. The ability to order and receive the results expedites Biodesix’s proteomic testing directly to and from the Lung Cancer Orchestrator at the same time it adds new insights on nodule risk of malignancy to further support the decision-making process.

Lung Cancer Orchestrator is part of Philips’ expanding portfolio of integrated cancer care solutions that seamlessly connect data, technology, operations, and clinical workflows to enable pivotal decision-making. Visit Philips Oncology to learn how Philips combines smart diagnostic and imaging technologies with connected workflows that integrate patient data from disparate systems, to provide solutions that put expert information at clinicians’ fingertips to help expand the quality and reach of personalized cancer care.

[1] International Agency for Research on Cancer, World Health Organization. Press Release N° 263. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. 12 September 2018
[2]https://www.medicinenet.com/what_is_the_most_survivable_cancer/article.htm
[3] International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med. 2006;355:1763- 1771 DOI: 10.1056/NEJMoa060476.
[4] Lane E, et al. Nearly twice as many people are now eligible for lung cancer screenings—here is what you need to know. Advisory Board publication. 2021.Washington, DC. https://www.advisory.com/sponsored/lung-cancer
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665735/
[6] Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020;371:m4087 http://dx.doi.org/10.1136/bmj.m4087


For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.

Attachment

OKX launches Block Trading as latest innovation for institutional and pro crypto traders

  • Block Trading is OKX’s latest innovation designed to allow institutional and professional traders to transact in bulk, without the risk of price slippage
  • OKX offers the only block trading platform for crypto that integrates spot and derivatives trading while supporting futures, options, and perpetual swap trading

VICTORIA, Seychelles, June 30, 2022 (GLOBE NEWSWIRE) — OKX, the world-leading cryptocurrency platform, today launched Block Trading, which allows professional and institutional users to execute large, privately negotiated transactions off the order books.

OKX is the only crypto exchange to provide a block trading platform that allows investors to execute crypto spot, futures, options, and perpetual swap trades, as well as multi-leg combination trades, over the counter. When executing multi-leg trading strategies on the platform, traders benefit from competitive pricing and ease of use, including single-click atomic trade execution. Since trades are executed over the counter, traders avoid the risk of price slippage — the divergence of quoted sell price and actual sell price.

The OKX Block Trading platform is distinctive in that it allows users to integrate spot and derivatives trades on a single platform and trade multiple currencies in a single trade. It is also unique for its support of trading of perpetual swap, futures, and option contracts with popular altcoins, such as Solana (SOL), as the underlying. The platform allows for multi-leg combination trades, including future spreads, straddles and carry trades, among others.

Lennix Lai, Financial Markets Director, OKX, said, “As the crypto market matures and more professional and institutional investors enter it, OKX is introducing Block Trading to ensure these users have the tools they need to invest well. Block Trading on OKX allows investors to not only make large trades at more favorable prices, but to do so without the risk of their trading causing price slippage.”

To execute a block trade on OKX, traders first submit a request-for-quote (RFQ) that broadcasts their request to selected counterparties, who then offer a quote in response. If the trader accepts the quote, the trade is then executed off the order books via OKX’s trading engine. Investors can discover more about how OKX Block Trading works on OKX Learn.

Clément Florentina, CEO, Darley Technologies, said, “OKX has always been one of the most user-friendly exchanges for institutional traders like ourselves, with features like portfolio margin providing greater capital efficiency. Block Trading on OKX opens up additional opportunities for us to quote sophisticated, multi-instrument strategies, without the counterparty having to worry about slippage or execution.” Darley Technologies is a high-frequency trading firm that delivers market making and liquidity provision on a range of prominent exchanges.

Going forward, Block Trading on OKX will be expanded to offer bespoke strategies, further OTC products and integrations with Dei derivatives protocols.

OKX is the world’s most powerful crypto exchange for institutional traders, ranking second globally in derivatives trading volume. The platform was also the first to introduce portfolio margin mode for multi-currency margining with risk offsetting functionality, and offers 500+ spot pairs and 250+ linear and inverse perpetual swaps and futures contracts.

Find out more about OKX Block Trading here.

For further information, please contact:
Media@okx.com

About OKX
OKX is a world-leading crypto trading app and Web3 ecosystem. Trusted by more than 20 million global customers in over 180 international markets, OKX is known for being the fastest and most reliable crypto trading app of choice for investors and professional traders globally.

Since 2017, OKX has served a global community of people who share a common interest in participating in a new financial system that is designed to be a level playing field for everyone. We strive to educate people on the potential of crypto markets and how to invest and trade responsibly. Beyond the OKX trading app, our Web3 portal, known as OKX Wallet, is our latest offering for people looking to explore the world of DeFi, NFTs and the metaverse.

To learn more about OKX, download our app or visit: okx.com

N2Growth Expanding Executive Search & Leadership Advisory Operations Into Mexico, Acquires FluidMind Consulting

Firm Appoints Former Korn Ferry & Spencer Stuart Executive as Managing Partner.

N2Growth

N2Growth

PHILADELPHIA, June 30, 2022 (GLOBE NEWSWIRE) —  N2Growth Inc., a global leadership consulting and executive search firm, announced today the expansion to Mexico with its acquisition of the Mexican talent and leadership advisory firm, FluidMind Consulting, appointing Carlos Alfonso Gonzalez as Managing Partner. Carlos will be responsible for all operations in Mexico and neighboring countries and will report directly to Kelli Vukelic, Chief Executive Officer at N2Growth.

“In today’s ultra competitive global climate, our clients entrust us to help them find top leaders who can build notable leadership teams who can drive exceptional performance from all corners of the globe, and Mexico is no exception.” Mr. Gonzalez has extensive experience identifying talent in the Latin American region and has a track record of success serving clients globally, particularly in the technology and professional services industries. “Furthermore, FluidMind Consulting’s leadership advisory practice was a perfect fit for our firm’s mission and philosophy: to find the best leaders by first identifying their leadership DNA”, said Kelli Vukelic, Chief Executive Officer at N2Growth.

The firm’s new location will be headquartered in Mexico City and led by Mr. Carlos Alfonso Gonzalez, Founder of FluidMind and former Korn Ferry and Spencer Stuart executive with over 20 years of professional experience in executive search, coaching, and leadership assessment. In 1998 he launched Korn Ferry Mexico’s technology practice and led it for Latin America until 2009. He was a member of the company’s global technology leadership council. He also headed the technology, telecom, media & entertainment practice at Spencer Stuart Mexico in 2011. He returned to Korn Ferry to lead the firm’s strategic, global relationship with Microsoft. Throughout his career, he has placed, coached, and mentored professionals and corporate athletes throughout Latin America who have subsequently grown into continental and global roles.

Founded in 2018, FluidMind is an executive search and leadership advisory firm in Mexico City, MX, that Mr. Gonzalez founded. FluidMind’s expertise is in executive search, executive assessment, talent solutions, and coaching at the C-Suite level. FluidMind made a name for itself by supporting organizations in evaluating talent and preparing businesses for the future of leadership, working with prominent brands, including Microsoft, Accenture, Diebold Nixdorf, Rackspace, Dell, NTT Ltd., and Pure Storage.

“This acquisition was destined to happen as there is full compatibility between both companies’ values and philosophy on how to serve our clients best. It creates a platform for us to bring avant-garde solutions for highly-demanding clients who invest in attracting and developing leaders when talent is of the essence to crystallize their vision and make it actionable,” said Carlos.

N2Growth’s acquisition of FluidMind solidifies the firm’s commitment to building and establishing permanent operations throughout Latin America and supporting our vast global network of premiere talent through retained search engagements, executive coaching, and leadership assessments.

Carlos will be establishing the new location with his partner Juan Carlos Gonzalez who is joining N2Growth as a Consultant in the Leadership Development & Assessment practice. Juan Carlos has been a pivotal player in executing crucial Leadership Development projects and a valuable contributor in coaching several country managers and C-suite executives in the technology and startup arena who are facing challenges engaging the newer generations.

About N2Growth

N2Growth is a global leadership consulting and executive search firm, consistently ranked in the Top 10 of America’s Best Executive Recruiting Firms by Forbes. N2Growth serves more than 50 markets across the Americas, EMEA, and APAC. For more information visit www.n2growth.com.

Media Inquiries:

Dan Evans

CMO, N2Growth

press@n2growth.com

Related Images

Image 1: N2Growth

This content was issued through the press release distribution service at Newswire.com.

Attachment

Sydney Secures South by Southwest® Festival (SXSW®) Annual Event From 2023

The world’s most iconic conference and festival of creativity expands from North America for the first time in its 36-year history, with a new annual event in Sydney, Australia, showcasing the Asia Pacific’s pre-eminent music, screen, gaming, tech & innovation.

SXSW Sydney 2023

SXSW Sydney 2023

SYDNEY, June 30, 2022 (GLOBE NEWSWIRE) — Destination NSW is excited to announce the world’s most iconic futurist conference and festival South by Southwest® (SXSW®) expands outside of North America for the first time ever to bring its renowned celebration of creativity and innovation to Sydney, Australia, from Sunday, October 15 to Sunday, October 22, 2023.

Secured by Destination NSW, the NSW Government’s tourism and major events agency, SXSW Sydney will gather the world’s most inspired thinkers, creators and innovators for an agenda-setting exploration of the best in Music, Screen, Gaming, Technology and Innovation. With keynotes and panel sessions to be revealed soon, SXSW Sydney will be 2023’s must-attend event for those seeking to discover and shape future trends, emerging technology, and access unrivalled international networking opportunities. Sydney will be abuzz with opportunities to attend over 1000 sessions, screenings and performances, activations and parties across the city.

SXSW Sydney will become the official annual Asia-Pacific instalment of SXSW®, which launched in 1987 in Austin, Texas, and has included speakers and artists such as Barack Obama, Jordan Peele, Dave Grohl, Michelle Obama, Taika Waititi, Brené Brown, Steven Spielberg, Mark Cuban, Lady Gaga, Christiane Amanpour, Esther Perel, Jennifer Doudna, Prince, Michelle Yeoh, Ava DuVernay, Maria Ressa, Amy Webb, Billie Eilish, Melinda Gates, Elizabeth Warren and Snoop Dogg.

With a welcoming and vibrant energy, coupled with a uniquely distinct mix of iconic attractions, stunning natural landscapes, and status as the major events capital of the Asia Pacific – there is no better city than Sydney to host SXSW’s next chapter. As Australia’s only truly global city and gateway for international arrivals, Sydney’s cultural diversity makes it the perfect incubator for creative ingenuity. Sydney continues to lead the way in tech-innovation, boasting an eclectic creative footprint, ranking second in Asia for fin-tech development, and sixth globally*.

Stuart Ayres, MP, Minister for Enterprise, Investment and Trade, Minister for Tourism and Sport and Minister for Western Sydney, says: “Sydney is the economic and leisure gateway to Australia and a leader in tech innovation, with a global reputation for hosting major international events that capture the world’s attention. SXSW Sydney will provide significant benefits for the NSW visitor economy, with unparalleled networking opportunities to advance our tech and creative industries. The very best of the creative and tech industries in the Asia Pacific will be on display during SXSW Sydney, highlighting why Sydney is recognised as a global hub of tech, innovation and creative industries. SXSW Sydney will be a dual-purpose event that fosters industry innovation while also drawing thousands of people from around the world to enjoy our spectacular Harbour City. It will put a spotlight on Sydney as the major events and creative industries capital of the Asia Pacific, as well as being its premier business and lifestyle destination.”

As one of the world’s most vibrant cities, Sydney is the leading connector to innovation and creativity in the Asia-Pacific region and will become the must attend hub for uncovering what’s next in Music, Screen, Gaming, Tech and Innovation at SXSW Sydney in October 2023. Industry professionals, talent, partners and more can register their interest now to discover the unexpected ideas and diverse discussions SXSW Sydney makes possible when creative people come together.

REGISTER FOR FURTHER INFORMATION HERE

SXSW SYDNEY

WEBSITELINKEDINFACEBOOKINSTAGRAMTWITTER

SXSW SYDNEY

IN PARTNERSHIP WITH SXSW AUSTIN, TEG, & DESTINATION NSW

OCTOBER 15-22, 2023

SYDNEY, AUSTRALIA

For more information on the host city of SXSW Sydney, go to www.sydney.com. Get social using @sydney #feelnewsydney #ilovesydney

*Source: Australia is now ranked second in Asia for fintech development, and sixth globally.

 Why Australia 2021 Benchmark Report

Media contact:

Wayne Mitcham, Destination NSW  – wayne@amio.nz

Related Images

Image 1: SXSW Sydney 2023

This content was issued through the press release distribution service at Newswire.com.

Attachment

Constellation Brands Announces Agreement With Sands Family to Eliminate Class B Common Stock

Agreement provides multiple benefits including Corporate governance enhancements and operating cost savings

VICTOR, N.Y., June 30, 2022 (GLOBE NEWSWIRE) — Constellation Brands (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that following the recommendation of a special committee comprised solely of independent directors, its Board of Directors has approved, and will recommend to shareholders for approval, a proposal to eliminate the company’s Class B common stock. The proposed transaction contemplates that each outstanding share of the company’s Class B common stock, including those owned by the Sands Family, will be converted into the right to receive one share of Class A common stock plus cash consideration in the amount of $64.64 per share of Class B common stock, or a total amount of $1.5 billion. This represents a 26.5% premium relative to Constellation’s Class A common stock closing share price as of June 29, 2022.

The Company expects to realize a number of corporate governance and other benefits from the proposed reclassification, including:

  • the elimination of the higher vote Class B common stock, including the associated voting control of the Sands Family, and a reduction in the concentration of voting power
  • simplification of the Company’s equity capital structure to better align the voting rights and interests of all shareholders
  • broader appeal of its shares to a larger base of investors who prefer single voting class common stock structures
  • operating cost savings associated with executive salary and certain benefits ($15-20 million of cost in fiscal 2022), as well as administrative savings from maintaining the Class B common stock
  • rotation of the lead independent director position on the Board at the next available normal cycle opportunity
  • shift to majority voting in uncontested elections from current plurality standard for its Board of Directors and adoption of a Board anti-pledging policy

In addition, upon completion of the reclassification, Robert and Richard Sands, who currently serve as Executive Chairman of the Board and Executive Vice Chairman of the Board, respectively, will retire from their employment with Constellation Brands in their current executive capacities. Robert Sands will become Non-Executive Chairman of the Board and Richard Sands will continue on as a Board member. It is expected that the Sands Family will continue to be Constellation’s largest shareholder following completion of the reclassification. Following the reclassification, the Sands Family will be subject to customary standstill provisions.

“After an extensive review and analysis by a Special Committee of the Constellation Brands Board of Directors, including input from an independent financial advisor and legal counsel, the Board agreed it is in the best interests of the Company and all Constellation shareholders, to eliminate the Class B common stock,” said Bill Newlands, Constellation’s President and CEO. “The proposed share reclassification will strengthen the Company’s corporate governance profile by aligning voting rights with the economic interests of all shareholders. In addition, the Company’s simplified capital structure will provide a solid foundation as the Company continues to pursue its strategic growth initiatives and capital allocation priorities to build shareholder value.”

This reclassification will not be put to a vote at the upcoming 2022 Annual Meeting of Shareholders. Instead, the Company will be seeking shareholder approval of the reclassification at a Special Meeting of Shareholders, to be held following effectiveness of a registration statement to be filed with the Securities and Exchange Commission. The reclassification is subject to the approval of a majority of the outstanding shares of Class A and Class B common stock, voting together as a single class, a majority of the outstanding shares of Class B common stock, and a majority of the issued and outstanding shares of Class A common stock not held by the Sands Family, executive officers of Constellation or directors that hold Class B common stock.

A complete description of the reclassification will be included in the proxy statement for the Special Meeting. The Company will announce details of the Special Meeting as soon as it is determined.

Centerview Partners LLC served as financial advisor and Potter Anderson & Corroon LLP served as legal counsel to the Special Committee of the Constellation Board of Directors. Greenhill & Co served as financial advisor and Wachtell, Lipton, Rosen & Katz served as legal counsel to the Sands Family. Kirkland & Ellis LLP served as legal counsel to Constellation.

ABOUT CONSTELLATION BRANDS
At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, our fine wine and craft spirits brands, including The Prisoner Wine Company, Robert Mondavi Winery, Casa Noble Tequila, and High West Whiskey, and our premium wine brands such as Meiomi, and Kim Crawford.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

Important Additional Information
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Constellation intends to file with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-4, which will contain a proxy statement/prospectus in connection with the proposed reclassification. STOCKHOLDERS OF CONSTELLATION ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain a free copy of the proxy statement/prospectus (when available), as well as other filings containing information about Constellation, without charge, at the SEC’s website, www.sec.gov, and on Constellation’s Investor Relations website at https://ir.cbrands.com.

Participants in the Solicitation
The directors and executive officers of Constellation and other persons may be considered participants in the solicitation of proxies from stockholders in connection with the proposed transaction. Information regarding Constellation’s directors and executive officers is available in Constellation’s most recent proxy statement, dated May 27, 2022, for the Annual Meeting of Stockholders to be held on July 19, 2022, which was filed with the SEC on June 2, 2022, and Constellation’s other filings with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be contained in the proxy statement/prospectus when it becomes available.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements. The word “expect,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements may relate to future plans and objectives of management and Constellation’s Board of Directors, as well as information concerning expected actions of third parties. All forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those set forth in, or implied by, such forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur.

The forward-looking statements are based on management’s current expectations and should not be construed in any manner as a guarantee that such results will in fact occur. All forward-looking statements speak only as of the date of this press release and Constellation does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Statements in this press release regarding Constellation and the reclassification transaction that are forward-looking, including projections as to the anticipated benefits of the proposed transaction, the impact of the proposed transaction on Constellation’s business and future financial and operating results and capital structure following the closing of the proposed reclassification and the closing date for the proposed transaction, are based on management’s estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Constellation’s control. These factors include, among other things, (1) failure to receive the requisite approvals of Constellation’s shareholders necessary to achieve the reclassification; (2) any other delays with respect to, or the failure to complete, the reclassification; (3) the ultimate outcome of any litigation matter related to the reclassification, (4) the ability to recognize the anticipated benefits of the reclassification, (5) Constellation’s ability to execute successfully its strategic plans, and (6) the effect of the announcement or the consummation of the proposed reclassification on the market price of the capital stock of Constellation. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks that could cause actual future performance or events to differ from current expectations can be found in Constellation’s filings with the SEC, including the risk factors discussed in Constellation’s most recent Annual Report on Form 10-K for the fiscal year ended February 28, 2022.

To learn more, visit www.cbrands.com and follow us on Twitter, Instagram, and LinkedIn.

MEDIA CONTACTS INVESTOR RELATIONS CONTACTS
Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com
Amy Martin 585-678-7141 / amy.martin@cbrands.com
Patty Yahn-Urlaub 585-678-7483 / patty.yahn-urlaub@cbrands.com
Joseph Suarez 771-551-4397 / joseph.suarez@cbrands.com

A downloadable PDF copy of this news release can be found here: http://ml.globenewswire.com/Resource/Download/d48d1261-28d3-4e5e-a0fa-ca15cb6aa9f4

Constellation Brands Reports First Quarter Fiscal 2023 Financial Results

VICTOR, N.Y., June 30, 2022 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, reported today its first quarter fiscal 2023 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson, on Thursday, June 30, 2022 at 10:30 a.m. EDT. Visit ir.cbrands.com to locate information for joining the conference call or a live, listen-only webcast of the conference call.

ABOUT CONSTELLATION BRANDS
At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, our fine wine and craft spirits brands, including The Prisoner Wine Company, Robert Mondavi Winery, Casa Noble Tequila, and High West Whiskey, and our premium wine brands such as Meiomi, and Kim Crawford. But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

A PDF containing our First Quarter Fiscal Year 2023 Results and full financial tables is available at: http://ml.globenewswire.com/Resource/Download/bc9fb20c-c947-482b-bda0-f501426fccc8

MEDIA CONTACTS INVESTOR RELATIONS CONTACT
Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com
Amy Martin 585-678-7141 / amy.martin@cbrands.com
Joseph Suarez 773-551-4397 / joseph.suarez@cbrands.com

Cellebrite Launch of Physical Analyzer Ultra Series Transforms Industry Standard for Digital Data Examination

With recent launches of Physical Analyzer Ultra Series and SaaS-based Cellebrite Premium, Cellebrite delivers powerful, end-to-end Collect & Review offering for digital investigations

PETAH TIKVA, Israel and TYSONS CORNER, Va., June 30, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the general availability of the Cellebrite Physical Analyzer Ultra Series (PA Ultra Series), the next generation of PA and the de-facto industry standard for digital data examination.

PA Ultra Series is a revolutionary solution that further empowers investigators to uncover key pieces of case-relevant digital evidence and examine digital data more efficiently, to help secure more convictions, accelerate justice, and close cases faster. PA Ultra Series will significantly boost Cellebrite’s Collection & Review offerings as part of the Digital Intelligence suite of solutions.

PA Ultra Series will enable investigation teams to leverage an upgraded solution that can process a higher volume of computer, cloud, and mobile data, allow cases to be opened without the need to reparse data and support multiple cases and evidence per device with enhanced location data from a new customizable dashboard. PA Ultra will also enable data enrichment for cryptocurrency, ranging from leading blockchain data platforms to tracking transactions.

Ronnen Armon, Chief Products & Technologies Officer, said: “PA Ultra Series transforms PA’s data processing, decoding, and reporting capabilities. We are confident that our continued innovation will empower examiners and law enforcement agencies to make more efficient and insightful investigative decisions that will lead to uncovering the truth and securing more convictions.”

Additionally, after successful beta testing and showcasing the pre-release, the SaaS version of Cellebrite Premium, an industry-leading advanced access solution, is now available for customers. With the general release of PA Ultra Series and the general availability of a SaaS-based version of Cellebrite Premium, Cellebrite has built upon its position as the global leader in the Digital Intelligence market. The Company provides a complete Collection & Review technology stack to its public and private sector customers, dramatically boosting our customer’s ability to analyze data in investigations and manage this process in the cloud.

For more information on Cellebrite PA Ultra Series, please visit https://cellebrite.com/en/pa-ultra.

For more information on Cellebrite Premium-as-a-Service, please visit: https://cellebrite.com/en/premium-as-a-service/.

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Caution Regarding Forward Looking Statements

This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on form 20-F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Cellebrite Contacts

Media
Victor Cooper
Public Relations and Corporate Communications Director
Victor.cooper@cellebrite.com
+1 404.804.5910

Investors
Anat Earon-Heilborn
VP Investor Relations
+972 73 394 8440
investors@cellebrite.com